PHARMA TECH

Vow Inc. joins portfolio of K1, a leading investment firm focusing on high-growth software companies globally

Digital Pharmacist | October 11, 2021

Vow Inc. joins portfolio of K1, a leading investment firm focusing on high-growth software companies globally
Vow, a leading provider of interactive phone systems to the pharmacy industry, announced its strategic partnership with Digital Pharmacist, a software company that powers digital communication and adherence solutions for over 7,000 pharmacies. Together, the combined businesses establish an industry leading portfolio of solutions that automate pharmacy operations and enhance patient communications through its core solutions: Patient Engagement Platform, interactive voice response (IVR), website, and mobile app.

We are thrilled to partner with Digital Pharmacist, it's an exciting opportunity to further expand our offerings and build innovative products, This next chapter of growth will accelerate our business and development, allowing our current customers and the rest of the pharmacy industry to experience the benefits. We remain highly committed to the pharmacy community and see that the Digital Pharmacist team shares the same level of commitment.

- Chip Simmons, the founder of Vow, who will lead the combined IVR business.


Vow will continue to offer its best-in-class IVR technology platform. It will subsume Digital Pharmacist's IVR operations and products, migrating the company's customers to Vow's platform in 2022. Digital Pharmacist will subsume Vow's website and mobile app solutions, augmenting these products with new features and functionality that will enrich patient engagement and experience.

We are excited to partner with Chip and the Vow team to bring the Vow brand and products to a greater number of independent pharmacies, Digital Pharmacist's strategic combination with Vow positions us to deliver best-in-class interoperable IVR, website, and mobile app products to our pharmacy customers and their patients. Our next-generation Patient Engagement Platform will form the cornerstone of our product platform.

- Corey Hansen, CEO of Digital Pharmacist.

About Vow
Vow, headquartered in Boiling Springs, South Carolina, is a leading provider of interactive phone systems to the pharmacy industry where its solutions operate in nearly two-thousand pharmacies. The company's products automate operations, improve pharmacists' productivity, and improve patient experience.

About Digital Pharmacist
Digital Pharmacist, headquartered in Austin, Texas, is a leading provider of software to the pharmacy industry where its solutions are deployed across more than seven thousand pharmacies. The company's products drive patient engagement and improve patient outcomes.

Spotlight

When it comes to safely and securely transporting high value pharmaceutical products, the stakes couldn’t be higher. Not only is a single consignment of high value drugs potentially worth upwards of $50 million, but, for those patients in need of these drugs, ensuring these products arrive on time and in optimal condition is quite literally a matter of life and death.

Spotlight

When it comes to safely and securely transporting high value pharmaceutical products, the stakes couldn’t be higher. Not only is a single consignment of high value drugs potentially worth upwards of $50 million, but, for those patients in need of these drugs, ensuring these products arrive on time and in optimal condition is quite literally a matter of life and death.

Related News

DTx Pharma to Present at the Chardan Virtual 4th Annual Genetic Medicines Event

Prnewswire | September 29, 2020

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and will participate in 1x1 meetings at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5th, 2020 at 4:45 pm EDT. "At DTx, we are focused on treating the genetic drivers of disease by applying our FALCON technology platform to expand the therapeutic utility of oligonucleotides," said Dr. Suckow. "We look forward to presenting our company at the Chardan Genetic Medicines event and demonstrating the disruptive potential of our FALCON platform in creating the next wave of RNA-based therapeutics."

Read More

Leo Lens Pharma Excited to Have Its Lead Asset Ready for Human Clinical Evaluation

Leo Lens Pharma | June 23, 2020

Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one week. After a productive Pre-IND meeting with the FDA, Leo Lens has now successfully completed GLP biocompatibility studies required by the FDA, secured a clinical research organization to oversee the initial human clinical trial, secured the clinical site, and executed an agreement with a contract manufacturing organization for cGMP manufacturing of the clinical test articles. The company plans to submit an IND in the coming months and proceed to Phase 2a clinical evaluation of LL-BMT1 in 2020.

Read More

Additive Orthopaedics® Announces additive manufacturing Capability with Patient Specific Implant Locking Technology

Additive Orthopaedics, LLC | October 23, 2020

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants. The patent pending technology can be incorporated in Additive Orthopaedics Patient Specific 3D Printed Plates and Patient Specific 3D Printed Bone Segments. According to Luciano Bertolotti, Director of Engineering for Additive Orthopaedics, "Locking technology is straightforward for off the shelf implants in which the machining process for the screw hole threads is set up once and can be manufactured in high volumes.

Read More